These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 9625483)
1. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. Denny WA; Wilson WR J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483 [TBL] [Abstract][Full Text] [Related]
2. Prodrug strategies in cancer therapy. Denny WA Eur J Med Chem; 2001; 36(7-8):577-95. PubMed ID: 11600229 [TBL] [Abstract][Full Text] [Related]
3. Tumor-activated prodrugs--a new approach to cancer therapy. Denny WA Cancer Invest; 2004; 22(4):604-19. PubMed ID: 15565818 [TBL] [Abstract][Full Text] [Related]
4. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Connors TA Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009 [TBL] [Abstract][Full Text] [Related]
5. Beta-glucuronidase-mediated drug release. de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215 [TBL] [Abstract][Full Text] [Related]
6. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273 [TBL] [Abstract][Full Text] [Related]
7. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. Tietze LF; Schmuck K Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425 [TBL] [Abstract][Full Text] [Related]
9. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies. Tietze LF; Krewer B Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523 [TBL] [Abstract][Full Text] [Related]
10. Targeted prodrug approaches for hormone refractory prostate cancer. Aloysius H; Hu L Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338 [TBL] [Abstract][Full Text] [Related]
12. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). Hay MP; Wilson WR; Denny WA Bioorg Med Chem Lett; 1999 Dec; 9(24):3417-22. PubMed ID: 10617083 [TBL] [Abstract][Full Text] [Related]
13. Prodrugs: a challenge for the drug development. Zawilska JB; Wojcieszak J; Olejniczak AB Pharmacol Rep; 2013; 65(1):1-14. PubMed ID: 23563019 [TBL] [Abstract][Full Text] [Related]
15. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Springer CJ; Antoniw P; Bagshawe KD; Wilman DE Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165 [TBL] [Abstract][Full Text] [Related]
16. Strategies for enzyme/prodrug cancer therapy. Xu G; McLeod HL Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842 [TBL] [Abstract][Full Text] [Related]
17. The role of hypoxia-activated prodrugs in cancer therapy. Denny WA Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684 [TBL] [Abstract][Full Text] [Related]
18. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Springer CJ; Niculescu-Duvaz I Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927 [TBL] [Abstract][Full Text] [Related]
19. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Denny WA Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798 [TBL] [Abstract][Full Text] [Related]